Lenvervimab
Lenvervimab (INN;[1] development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.[2]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | hepatitis B virus surface antigen |
| Clinical data | |
| Other names | GC1102 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
This drug is being developed by GC Pharma. As of 2018, lenvervimab is undergoing Phase II/III trials.
References
- World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
- Jeong GU, Ahn BY, Jung J, Kim H, Kim TH, Kim W, Lee A, Lee K, Kim JH (2020). "A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants". PLOS ONE. 15 (8): e0236704. Bibcode:2020PLoSO..1536704J. doi:10.1371/journal.pone.0236704. PMC 7425877. PMID 32790777.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.